Republic of Bashkortostan

Republic of Bashkortostan
in numbers
Foreign investors
in Republic of Bashkortostan

Related Reading

Document name
Investment Guide to the Republic of Bashkortostan
EN 2020
The Ministry of Economic Development and Investment Policy of the Republic of Bashkortostan
Address: 450101, the city of Ufa, 46 Tukaeva Str.
Tel.: +7 (347) 280-83-06
Fax: +7 (347) 280-87-00
Time zone: Москва +2


The Republic of Bashkortostan Development Corporation, JSC
Address: 450077, Russia, Republic of Bashkortostan, Ufa, Verhnetorgovaya square, 6
Tel.: +7 (347) 214 90 70



Barbaros Motor, a Turkish investor, is currently considering two sites in Bashkiria to set up production of equipment and spare parts for the agriculture. The Regional Development Corporation told RBC Ufa that the investor estimates the initial project investment at $2.5 mn (or RUB 182.2 mn rubles at the exchange rate as of September 18).
On Friday, August 6, President Vladimir Putin took part in the opening ceremony for Cemix plant of dry construction mixes in the Abzelilovsky District of Bashkiria. The head of state visited the company during his working visit to the republic and the Chelyabinsk region.
Kronospan Holdings East Ltd. is considering prospects of increasing production output in Bashkiria and planning to invest RUN 18.4 bn in the projects, as First Deputy Prime Minister of Bashkiria - Head of the Government Administration Ilshat Tazhitdinov told Interfax.
McDonald's fast food chain intends to invest up to RUB 650 million in the next 5 years in the development of its structure in Bashkiria, according to the press office of the republican government.
Lasselsberger LLC, a subsidiary of Lasselsberger Group, Austria, wishes to invest RUB 6.3 billion in the expansion of ceramic tile production in the Ufa Region, Government of Bashkiria’s press office says.
Pfizer and Pharmstandard signed an agreement on contract manufacturing in Russia (at Pharmstandard-UfaVITA’s Bashkortostan plant) of innovative drugs for the treatment of breast cancer, lung cancer, kidney cancer and chronic myeloid leukemia. Pharmstandard-UfaVITA will provide the partner with product development services. The first commercial batches are expected in 2024.

Select a region